Clinical Trial Update: Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of carbamylated erythropoietin (CEPO) in patients with acute ischemic stroke has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Carbamylated Erythropoietin (CEPO) (carbamylated erythropoietin)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Acute Ischemic Stroke | Phase 1 | Status: COMPLETED